Revolutionizing Drug Discovery: Anthropic Takes on Big Pharma's Most Neglected Diseases
Anthropic is launching its own drug development programs to tackle diseases that traditional pharmaceutical companies deem unprofitable, with the potential to cut development time by up to 40%. This move marks a significant shift in the company's nonprofit mission, leveraging AI to accelerate medical research and improve treatment options for neglected diseases.
Anthropic is launching its own drug development program for neglected diseases that the pharmaceutical industry considers unprofitable. Novartis CEO Vas Narasimhan thinks AI could cut development time from twelve years to seven or eight and double the success rate from 8 to 16 percent. The article Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable appeared first on The Decoder.